OCT 14, 2020 2:30 PM SGT

Detection and Treatment Prediction of Pancreatic Cancer Using a Glycan Biomarker​

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor, Van Andel Institute, Center for Cancer and Cell Biology
    Biography

      Dr. Brian Haab is a Professor in the Center for Cancer and Cell Biology at the Van Andel Institute (VAI) in Grand Rapids, Michigan. His research is on the identification and detection of subtypes of pancreatic cancer using glycan biomarkers. The laboratory studies blood plasma, tumor tissue, and cyst fluid using novel glycan analysis technologies to deliver biomarkers for 1) earlier and more accurate diagnoses and 2) improved prediction of tumor behavior and drug responses. Dr. Haab received his PhD in chemistry from the University of California at Berkeley and completed postdoctoral training in the Department of Biochemistry at Stanford University before accepting a faculty position at the VARI in 2000.


    Abstract

    CA19-9 is widely known as being the best marker for pancreatic cancer having, on average, a 75% specificity and sensitivity. Three versions of a candidate biomarker related to CA 19-9 (sTRA), detected through screening via on-chip glycon profiling and their value in pancreatic cancer diagnosis are described. The distinct structural components of the sTRA versions, contrary to CA19-9, gives them a stem characteristic, indicating a potential role as subtype markers. Plasma levels of the biomarkers correlated with 45 matched samples, indicating the blood sample can be a good indicator of the primary tumor level. Combining the biomarkers together can detect more types of cancers than each alone, leading to improved sensitivity from 47% to 63%. Additionally, a statistically significant sensitivity increases over CA19-9 alone was noted in a blinded set. This is most rigorous validation so far of improvement upon CA 19-9 using upfront predefined thresholds and classification rules with statistically significant improvement. CA 19-9 provides prognosis value but lacks treatment prediction value. In contract, sTRA, demonstrates value for differentiating subtypes of cancers that is more resistant to chemo.

    Learning Objectives:

    • Understand the gaps in pancreatic cancer screening and how to overcome those gaps
    • sTRA demonstrates differentiating value when compared to CA19-9

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    JAN 21, 2021 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    Loading Comments...
    Show Resources